More options
Sort by relevance | Sorted by date: newest / oldest | Show use by person

Results 1-20 of 194 for pfizer

Economic Leadership for Cities — Motion to Take Note (11 December 2014)

Baroness Hollis of Heigham: ...such as ours need to grow our local economies? It is, of course, unitary status, as do Cambridge and Oxford, if we are to fulfil our potential to transform our knowledge economy into knowledge jobs. Who, in the recent Pfizer bid for Astra-Zeneca, spoke for Cambridge? Nobody. Combined authorities really work only where there are shared goals. Despite this, Norwich has formed a Greater...

Small Business, Enterprise and Employment Bill: Second Reading (2 December 2014) See 1 other result from this debate

Baroness Neville-Rolfe: ...proposals in the fourth money-laundering directive may have a wider application and require mutuals and co-operatives to obtain and hold more information in this area. The noble Lord, Lord Stevenson, asked what we are doing on takeovers. Following the AstraZeneca-Pfizer discussions, the Government said that they might need legislation to ensure that companies always honour big commitments....

Oral Answers to Questions — Business, Innovation and Skills: Topical Questions (11 September 2014) See 2 other results from this debate

Chuka Umunna: Sir David Barnes, former chief executive officer of AstraZeneca, told us both that while companies should manage their tax affairs efficiently, it should not have been the driving force for Pfizer’s proposed takeover of AstraZeneca because it was “a narrow basis on which to build an enduring and constructive business partnership.” Does the Business Secretary agree with that...

Bill Presented — Counsellors and Psychotherapists (Regulation) Bill: Small Business, Enterprise and Employment Bill (16 July 2014) See 1 other result from this debate

Vincent Cable: ...merger activity as a normal part of market processes, although I have to say that the evidence on the benefits of mergers is somewhat ambiguous. What emerged as a result of the recent high-profile case of AstraZeneca and Pfizer was a lack of clarity around the enforcement of assurances. The approach we adopted in Government was to talk to the company where issues of wider public interest...

Economy: Manufacturing — Motion to Take Note (3 July 2014)

Lord Monks: ...way in which it is dealing with Alstom and the assurances that it is getting from General Electric are a real object lesson. We would not have been in anything like the same position had the takeover of AstraZeneca by Pfizer gone ahead. We need to be as tough as other countries tend to be. It is interesting that the Business Secretary will be at the Economic Affairs Select Committee next week.

Oral Answers to Questions — Business, Innovation and Skills: Life Sciences (26 June 2014)

David Willetts: ...the world. We have been particularly successful in this country in making sure that as that happens we promote alternative investment, and we are now seeing—for example, in the facility that Pfizer operated in Kent—significant renewal as new, small businesses come in. Our life sciences strategy is attracting new investment to the UK—2 billion of it since we launched...

Queen’s Speech — Debate (4th Day) (10 June 2014)

Lord Tugendhat: ...fact, there have been two: one is the annexation of Crimea and all that Mr Putin has done in Ukraine and said about how Russian policy in its near abroad is likely to develop; and the other is the Pfizer bid for AstraZeneca. Let me take Russia first. In recent years, all EU member states have done business with Russia as if it is a country much like ours and becoming more so. Little or no...

Points of Order (14 May 2014)

Kevin Brennan: ...me, “I think he will find that the quotes that he has given are not accurate.” First, I did not read out any quotes in my question, and secondly, what I reported to the House about what the head of Pfizer said about job losses and cuts in research following a takeover is entirely accurate. Do we have any redress when the Prime Minister thinks that he can casually traduce an...

Oral Answers to Questions — Prime Minister: Engagements (14 May 2014) See 5 other results from this debate

Edward Miliband: ...the fall in unemployment. For all those people who have found work, it is good for them and good for their families. On the subject of high-skilled jobs in the UK, following the appearance of Pfizer at the Select Committee yesterday, can the Prime Minister tell us what further assurances he is seeking from Pfizer about its takeover of AstraZeneca?

Previous Business – Commons: Select Committee (14 May 2014)

Science and Technology: Proposed takeover of AstraZeneca. 9:15 am; The Thatcher Room, Portcullis House
Witnesses: Dr Mikael Dolsten, President, Worldwide Research and Development, Pfizer, Dr Rod MacKenzie, Group Senior Vice President, and Head of Pfizer PharmaTherapeutics Research and Development, Pfizer and Ian C Read, Chairman of the Board and Chief Executive Officer, Pfizer; Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca plc, Dr Mene Pangalos, Executive Vice President,...

Written Answers — House of Lords: NHS: Drugs and Medicines (14 May 2014)

Lord Oakeshott of Seagrove Bay: To ask Her Majesty’s Government what consideration they have given to using the purchasing power of the National Health Service as a major customer of AstraZeneca and Pfizer to ensure that Pfizer honours any undertakings given in the event of a successful takeover of AstraZeneca.

Previous Business – Commons: Select Committee (13 May 2014)

Business, Innovation and Skills: The future of AstraZeneca. 9:30 am; The Grimond Room, Portcullis House
Witnesses: Tony Burke, Assistant General Secretary, Unite and Allan Black, National Officer, GMB; Ian Read, Chairman and Chief Executive, Pfizer Inc., Frank D'Amelio, Executive Vice President, Business Operations and Chief Financial Officer, Pfizer Inc. and Jonathan Emms, UK Managing Director, Pfizer Inc.; Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca plc, Mene Pangalos,...

Written Answers — House of Lords: NHS: Drugs and Medicines (13 May 2014) See 1 other result from this answer

Lord Oakeshott of Seagrove Bay: ...’s Government, for each of the last three years for which figures are available, what was the total National Health Service expenditure on drugs and medicines produced by (1) AstraZeneca, (2) Pfizer, and (3) GlaxoSmithKline; and what percentage of the National Health Service’s total expenditure on drugs and medicines each of those figures represents.

Point of Order (8 May 2014)

Henry Smith: .... Yesterday, during Prime Minister’s questions, the right hon. Member for Doncaster North (Edward Miliband) raised the issue of the possible takeover of the pharmaceutical company AstraZeneca by Pfizer. It has since been reported that the Labour party has received significant donations from AstraZeneca. I seek your judgment on whether that should have been reported.

Business of the House (8 May 2014) See 4 other results from this debate

Angela Eagle: ...tell us what support the UK Government are offering to help locate and rescue these young women? On Tuesday, the Business Secretary told the House that he will not “rule out intervention” on Pfizer’s attempted takeover of AstraZeneca, which may threaten UK jobs in the strategically important pharmaceutical sector, but the Prime Minister seems to be a cheerleader for it....

Scottish Parliament: Life Sciences (8 May 2014) See 3 other results from this debate

Neil Bibby: ...expertise that we already have, not only in our universities but in our companies. One such company is AstraZeneca, which has its global headquarters here in the UK and is currently the subject of a 63 billion takeover bid by the American company Pfizer. That is the subject of the Labour amendment, and I note that the minister did not even reference that in his 10-minute speech....

Scottish Parliament: Decision Time (8 May 2014)

...Research Councils UK funding makes to scientific research at Scotland’s universities; believes that the UK Government should carry out a thorough assessment of the potential economic and scientific impact of Pfizer’s proposed takeover of AstraZeneca; recognises that a robust Scottish life sciences sector is dependent on a strong research base; notes that Scotland has...

Care Bill [HL]: Commons Amendments (7 May 2014)

Lord Owen: ...bioscience—is now at a very high level. Of course, it is because of this that there is a very strong debate over whether AstraZeneca should be taken over by the very large American pharmaceutical company Pfizer. However, we also have to recognise in this debate that without confidence and the free exchange of information in this world of science data, research will be very badly...

Oral Answers to Questions — Prime Minister: Engagements (7 May 2014) See 5 other results from this debate

Edward Miliband: There is deep concern in the British business and scientific communities about the proposed takeover of AstraZeneca by Pfizer. The deal would have an impact for decades to come on British jobs, British investment, British exports and British science. The Business Secretary said yesterday that he is “not ruling out intervention”. What type of intervention is under consideration by...

Written Answers — Business, Innovation and Skills: AstraZeneca: Pfizer (7 May 2014)

Ann McKechin: To ask the Secretary of State for Business, Innovation and Skills what discussions either orally or in writing he or his Ministers or officials in his Department have had with (a) Pfizer and (b) AstraZeneca in the last two months regarding any bid for AstraZeneca.

   More options
Sort by relevance | Sorted by date: newest / oldest | Show use by person